Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:C07H

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2021/203409NOVEL NON-HYGROSCOPIC LOW-VARIABILITY CRYSTALLINE FORM FOR TREATMENT OF HEPATITIS C
WO 14.10.2021
Int.Class C07H 19/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
19Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro derivatives thereof
02sharing nitrogen
04Heterocyclic radicals containing only nitrogen as ring hetero atom
06Pyrimidine radicals
10with the saccharide radical being esterified by phosphoric or polyphosphoric acids
Appl.No PCT/CN2020/084178 Applicant NANJING CHIA TAI TIANQING PHARMACEUTICAL CO., LTD. Inventor XU, Dan
A novel non-hygroscopic low-variability crystalline form for treatment of hepatitis C. The novel crystalline form T has a simple crystallization process, is easy for industrial production, and has no hygroscopicity. The use of a suitable preparation further prepared from the crystalline form T can significantly reduce the coefficient of variation of postprandial Cmax of a subject, so that the safety and effectiveness of a drug can be more reliably guaranteed.
2.WO/2021/206182COMPOUND, CONTRAST MEDIUM, AND METHOD FOR PRODUCING COMPOUND
WO 14.10.2021
Int.Class C07H 1/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
1Processes for the preparation of sugar derivatives
Appl.No PCT/JP2021/015216 Applicant ST. MARIANNA UNIVERSITY SCHOOL OF MEDICINE Inventor MATSUMOTO, Nobuyuki
The present invention pertains to a compound represented by formula (1) or a pharmaceutically acceptable salt thereof, wherein in formula (1), R1 to R3 each independently are a predetermined amino group, a predetermined amide group, or a group represented by formula (2), and at least one among R1 to R3 is a group represented by formula (2).
3.20210317424METHOD AND KIT FOR TEMPLATE-INDEPENDENT NUCLEIC ACID SYNTHESIS
US 14.10.2021
Int.Class C12N 9/12
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
9Enzymes, e.g. ligases (6.); Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating, or purifying enzymes
10Transferases (2.)
12transferring phosphorus containing groups, e.g. kinases (2.7)
Appl.No 17354543 Applicant Cheng-Yao CHEN Inventor Cheng-Yao CHEN

A method for synthesizing a nucleic acid includes providing an initiator having an unprotected nucleoside base and a 3′ hydroxyl group at a 3′ terminus, providing a nucleic acid polymerase having at least one conservative catalytic polymerase domain of a family-B DNA polymerase, providing at least one nucleotide monomer, and exposing the initiator to the nucleotide monomer in the presence of the nucleic acid polymerase, at a temperature ranging from 20° C. to 90°, and in the absence of a template, such that the nucleotide monomer is incorporated to the initiator to form the nucleic acid. Also disclosed is a kit includes the initiator, the nucleic acid polymerase, and the nucleotide monomer, and is used according to the method.

4.WO/2021/207085SYNTHETIC ELABORATION OF NATIVE DNA BY RASS (SENDR)
WO 14.10.2021
Int.Class C07H 21/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
21Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
Appl.No PCT/US2021/025799 Applicant THE SCRIPPS RESEARCH INSTITUTE Inventor DAWSON, Philip
Provided herein are methods for site selective chemical modification of an oligonucleotide comprising immobilizing the oligonucleotide on an inert resin to form oligonucleotide-resin complex; and contacting the oligonucleotide-resin complex with a phosphorus (V) based phosphorus (V) reagent in an organic solvent to produce a modified oligonucleotide. Further provide herein are methods of targeting delivery of an oligonucleotide therapeutic to a specific location in the patient body, and/or improving stability and half life of an oligonucleotide therapeutic by using modified oligonucleotides.
5.WO/2021/205631STING AGONISTIC COMPOUND
WO 14.10.2021
Int.Class A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
Appl.No PCT/JP2020/016064 Applicant ONO PHARMACEUTICAL CO., LTD. Inventor HANADA, Ryosuke
The present invention addresses the problem of providing a pharmaceutical having, as an active ingredient, a compound having agonistic activity on STING. As a result of having performed thoroughgoing studies, the inventors discovered, as substances capable of overcoming the aforestated problem, compounds represented by general formula (I-1) (in the formula, all the symbols represent the same meanings as those described in the specification) having agonistic activity on STING, and completed the present invention. The compounds represented by general formula (I-1) of the present invention have agonistic activity on STING, therefore, can be used as an active ingredient in an agent for suppressing the progress of, suppressing the recurrence of, and/or treating a cancer or an infectious disease.
6.20210317157Substituted Alloxazine Nucleosides and Nucleotides, and Methods of Making Same
US 14.10.2021
Int.Class C07H 19/23
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
19Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro derivatives thereof
02sharing nitrogen
04Heterocyclic radicals containing only nitrogen as ring hetero atom
23Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14-C07H19/22222
Appl.No 17224728 Applicant THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE Inventor Robert D. Kuchta

The present disclosure includes nucleosides and/or nucleotides comprising an optionally substituted alloxazine (also known as benzo[g]pteridine-2,4(1H,3H)-dione, or isoalloxazine) at the anomeric position.

7.WO/2021/205155C5-MODIFIED THYMIDINES
WO 14.10.2021
Int.Class C07H 19/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
19Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro derivatives thereof
02sharing nitrogen
04Heterocyclic radicals containing only nitrogen as ring hetero atom
06Pyrimidine radicals
10with the saccharide radical being esterified by phosphoric or polyphosphoric acids
Appl.No PCT/GB2021/050839 Applicant NUCLERA NUCLEICS LTD Inventor CHUN HAO CHEN, Michael
The present invention relates to a compound according to Formula (1c) or (1d): wherein, R1, R2, R3 and R4 are disclosed herein.
8.WO/2021/2051565-POSITION MODIFIED PYRIMIDINES
WO 14.10.2021
Int.Class C07H 19/20
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
19Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro derivatives thereof
02sharing nitrogen
04Heterocyclic radicals containing only nitrogen as ring hetero atom
16Purine radicals
20with the saccharide radical being esterified by phosphoric or polyphosphoric acids
Appl.No PCT/GB2021/050840 Applicant NUCLERA NUCLEICS LTD Inventor CHEN, Michael Chun Hao
The present invention relates to a compound according to Formula (1c) or (1d): wherein, R1; R2; R3 and R6 are defined herein, and their use in methods of nucleic acid synthesis.
9.WO/2021/207062METHODS FOR DETECTING TARGET NUCLEIC ACIDS BY IN SITU HYBRIDIZATION AND A KIT THEREOF
WO 14.10.2021
Int.Class C07H 21/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
21Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
Appl.No PCT/US2021/025749 Applicant ADVANCED CELL DIAGNOSTICS, INC. Inventor MATA, Miguel Angel
A method of detecting target nucleic acids, including small non-coding RNAs (sncRNAs), microRNAs (miRNAs), small interfering RNAs (siRNAs), PIWI-interacting RNA (piRNA), or antisense oligonucleotides (ASO) molecules, in a cell, comprising a post-fixation step using an aldehyde-containing fixative after the initial fixation step prior to in situ hybridization.
10.2862955Acidos nucleicos manipulados y métodos de uso de los mismos
ES 08.10.2021
Int.Class C07H 21/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
21Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
04with deoxyribosyl as saccharide radical
Appl.No 18179157 Applicant ModernaTX, Inc. Inventor SCHRUM, Jason